Utama › Kanser Paru-paru › Nevada
Kajian klinikal Kanser Paru-paru di Nevada
11 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi di Nevada.
Bandar di Nevada
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- dan 25 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037), Reno
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06312137Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Renown Regional Medical Center, Reno
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07100080A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Cancer Care Specialists, Reno
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06119581Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Renown Regional Medical Center, Reno
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05624996Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Jun 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
Mengambil pesertaFasa 2
18 Minutes · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06031688LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- OptumCare Cancer Care at Seven Hills, Henderson
- dan 13 lagi
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Jan 2026 · NCT06073431Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Renown Regional Medical Center, Reno
Mengambil pesertaKajian pemerhatian
Umur 50 ke atas · Semua jantina · Dikemas kini 5 Ogo 2025 · NCT06122077Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.